DavidScottMillerMDFACOG, FACS

Gynecologic Oncology

Amy and Vernon E. Faulconer Distinguished Chair in Medical Science, Dallas Foundation Chair in Gynecologic Oncology, Professor of Obstetrics & Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas, U.S.A.

Join to view full profile

Dr. Miller is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Miller's full profile

Already have an account?

Office
5323 Harry Hines Boulevard
Dallas, TX 75390
Phone+1 214-645-4673

Fax+1 214-645-2545

Summary

Dr. David Miller is an obstetrician/gynecologist in Dallas, TX and is affiliated with multiple hospitals in the area, including Parkland Health & Hospital System and University of Texas Southwestern Medical Center. He received his medical degree from University of Oklahoma College of Medicine and has been in practice 40 years. He specializes in gynecologic oncology and is experienced in gestational trophoblastic disease, ovarian neoplasms, reproductive and sexual endocrinology, general obstetrics and gynecology, and maternal and fetal medicine.

David Scott Miller

Amy and Vernon E. Faulconer Distinguished Chair in Medical Science Dallas Foundation Chair in Gynecologic Oncology Professor of Obstetrics & Gynecology Fred F.

Profile The Lens - Free & Open Patent and Scholarly Search

The Lens serves all the patents and scholarly work in the world as a free, open and secure digital public good, with user privacy a paramount focus.

Professor David Scott Miller - Kudos: Growing the influence of research

Kudos Personal Showcase for Professor David Scott Miller at University of Texas Southwestern Medical School, United States

David Scott Miller's Publons profile

View David Scott Miller's profile on Publons with 321 publications and 140 reviews.

David Miller - Deputy Group Chair for Membership and Research Integrity - NRG ON

View David Miller's profile on LinkedIn

David Scott Miller, M.D.: Obstetrics & Gynecology | Gynecologic Cancers | UT Sou

Early in his career, David Scott Miller, M.D., decided that his mission was helping women with their journey through cancer. He believes that no matter what the

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Gynecologic Oncology, 1983 - 1985
Drexel University College of Medicine/Hahnemann University HospitalResidency, Obstetrics and Gynecology, 1977 - 1981
Drexel University College of Medicine/Hahnemann University HospitalInternship, Obstetrics and Gynecology, 1977 - 1978
University of Oklahoma College of MedicineClass of 1977

Certifications & Licensure

CA State Medical License 1981 - Present
TX State Medical License 1991 - 2025
IL State Medical License 1985 - 1993
SC State Medical License 1982 - 1983
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com
Fellow (FACS) American College of Surgeons
Fellow (FACOG) American Congress of Obstetricians and Gynecologists

Clinical Trials

Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18
Recruiting
Phase 3
Collecting Tumor Samples From Patients With Gynecological Tumors Start of enrollment: 1992 Jun 01
Completed
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Start of enrollment: 2009 Sep 01
Active, not recruiting
Phase 3
Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Start of enrollment: 2010 Apr 01
Completed
Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Start of enrollment: 2010 Apr 12
Active, not recruiting
Phase 3
Biomarkers in Tissue Samples From Patients With Stage I or Stage III Endometrial Cancer Start of enrollment: 2010 May 01
Unknown status
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Start of enrollment: 2011 Mar 14
Completed
Phase 1
Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node Dissection Start of enrollment: 2012 Jan 03
Active, not recruiting
Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva Start of enrollment: 2012 Jul 02
Active, not recruiting
Phase 2
A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer Start of enrollment: 2020 Jul 15
Completed
Phase 2
A Trial for Patients With Advanced/Recurrent Endometrial Cancer Start of enrollment: 2006 Sep 01
Completed
Phase 2
A Trial for Patients With Advanced/Recurrent Cervical Cancer Start of enrollment: 2005 Feb 01
Completed
Phase 2
Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Start of enrollment: 2003 Aug 25
Completed
Phase 3
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer Start of enrollment: 2000 Feb 01
Terminated
Phase 2
Topotecan in Treating Patients With Recurrent or Refractory Cancer of the Uterus Start of enrollment: 1998 Jun 01
Terminated
Phase 2
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Start of enrollment: 2008 Sep 01
Completed
Phase 2
Pemetrexed Disodium in Treating Patients With Persistent or Recurrent Endometrial Cancer Start of enrollment: 2006 May 01
Completed
Phase 2
Aminopterin in Treating Patients With Recurrent or Refractory Endometrial Cancer Start of enrollment: 1998 Jan 01
Withdrawn
Phase 2
Pemetrexed Disodium in Treating Patients With Recurrent Cancer of the Cervix Start of enrollment: 2004 Aug 01
Completed
Phase 2
Pemetrexed Disodium in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer Start of enrollment: 2004 Jul 01
Completed
Phase 2
Aminocamptothecin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Cancer of the Peritoneum Start of enrollment: 1999 Jan 01
Completed
Phase 2
A Trial for Patients With Gestational Trophoblastic Disease Start of enrollment: 2006 Jul 01
Completed
Phase 2
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 3
A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation Start of enrollment: 2020 Dec 21
Active, not recruiting
Phase 2
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Start of enrollment: 2014 Feb 27
Active, not recruiting
Phase 2, Phase 3
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Start of enrollment: 2010 Sep 27
Active, not recruiting
Phase 3
A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor Start of enrollment: 2019 Jul 11
Recruiting
Phase 1
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma Start of enrollment: 2023 Apr 18
Recruiting
Phase 3
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer Start of enrollment: 2019 Jul 16
Active, not recruiting
Phase 3
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors Start of enrollment: 2022 Oct 06
Recruiting
Phase 1, Phase 2
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2019 Sep 20
Recruiting
Phase 3
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies Start of enrollment: 2021 Dec 07
Recruiting
Phase 1, Phase 2
IMGN853 With Carboplatin in Second-line Treatment of FRα Expressing, Platinum-sensitive Epithelial Ovarian Cancer Start of enrollment: 2022 Sep 28
Active, not recruiting
Phase 2
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors Start of enrollment: 2017 May 25
Recruiting
Phase 3
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer Start of enrollment: 2022 Dec 07
Recruiting
Phase 3
Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma Start of enrollment: 2022 Nov 16
Recruiting
Phase 2, Phase 3
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation Start of enrollment: 2021 Sep 07
Recruiting
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer Start of enrollment: 2022 Mar 22
Recruiting
Not Applicable
Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix Start of enrollment: 2022 May 03
Recruiting
Not Applicable
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors Start of enrollment: 2021 Mar 18
Recruiting
Phase 1, Phase 2
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III Start of enrollment: 2021 Jan 01
Recruiting
Phase 2
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer Start of enrollment: 2019 Jul 16
Recruiting
Phase 1
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung Start of enrollment: 2022 Jun 28
Recruiting
Phase 2, Phase 3
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) Start of enrollment: 2017 May 02
Recruiting
Phase 1, Phase 2
A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab Start of enrollment: 2022 Jan 01
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

430 citations
Phase III Study of Cisplatin With or Without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study
David H. Moore, John A. Blessing, Richard P. McQuellon, Howard T. Thaler, David Cella
Journal of Clinical Oncology. 2004-08-01
142 citations
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.
Deborah K Armstrong, Ronald D Alvarez, Floor J Backes, Jamie N Bakkum-Gamez, Lisa Barroilhet
Journal of the National Comprehensive Cancer Network. 2022-09-01
97 citations
Modulation of p-glycoprotein transport function at the blood-brain barrier.
Björn Bauer, Anika M.S. Hartz, Gert Fricker, David S. Miller
Experimental Biology and Medicine. 2005-02-01

Other

Treatment of locally advanced, recurrent, or metastatic endometrial cancer
Miller DS, Campos SM
http://www.uptodate.com/contents/treatment-of-locally-advanced-recurrent-or-metastatic-endometrial-c
UpToDate, Wolters Kluwer Health - 2013-02-25

Authored Content

Dr Miller on the Efficacy of Selinexor in TP53 Wild-Type Endometrial CancerOctober 2024
Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO StudyAugust 2024
Miller Discusses the Use of Selinexor in TP53 Wild-Type Advanced Endometrial CancerJuly 2024
Video: A Discussion of the Rapidly Evolving Landscape in Endometrial Cancer: Addressing Clinical Changes, Challenges, and DisparitiesApril 2024
Slideset: A Discussion of the Rapidly Evolving Landscape in Endometrial Cancer: Addressing Clinical Changes, Challenges, and DisparitiesApril 2024
Expert Analyses of Key Clinical Developments and Updates Across Gynecologic Malignancies: Independent 2023 Conference/Congress CoverageDecember 2023
Predictors of Long-term Survival in Endometrial CancerDecember 2023
State-of-the-Art Management of Advanced or Recurrent Endometrial CancerNovember 2023
Radiation Therapy for Medically Inoperable Endometrial CancerOctober 2023
Immunotherapy in Endometrial Cancer: Current Progress and Future DirectionsAugust 2023
Outcomes in Older Women With Endometrial CancerAugust 2023
Quality of Life and Sexual Health in Endometrial Cancer SurvivorsJuly 2023
Frequently Asked Questions: Precision Medicine in Gynecologic CancersJune 2023
Minimally Invasive Surgery in Endometrial Cancer: Long-term Recurrence and SurvivalJune 2023
Applying Current Precision Medicine Strategies for the Treatment of Gynecologic CancersJune 2023
Applying Current Precision Medicine Strategies for the Treatment of Gynecologic CancersJune 2023
Integrating Biomarkers and Guideline-Aligned Treatment Approaches Into Patient-Centered Care for Advanced/Metastatic Endometrial CancerMay 2023
Expert Commentary and Insight on Key Data From SGO 2023 Informing Treatment for Endometrial, Cervical, and Ovarian CancersMay 2023
Expert Insight on New Data From SGO 2023 Informing Treatment for Endometrial, Cervical, and Ovarian CancersMay 2023
Slides: Expert Insight on Practice Changing Data From SGO 2023 Informing Treatment for Endometrial, Cervical, and Ovarian CancersMay 2023
Expert Analyses of Key Clinical Developments and Updates Across Gynecologic MalignanciesJanuary 2023
Endometrial Cancer Consult: Optimal Management Across the Disease ContinuumJanuary 2023
Treating Gynecologic Cancers: Current Approaches to Patient CareDecember 2022
CCO 2022 Global Conference Coverage: Gynecologic Cancer UpdatesNovember 2022
Evolving Treatment Paradigms for Gynecologic Malignancies: Application for Current and Future PracticeJune 2022
Gynecologic Cancers: Expert Guidance for Community PracticeMay 2022
FAQs: Integrating Novel Therapies Into the Management of Gynecologic CancersMay 2022
Expert Insight on Key Data From SGO 2022 Informing Treatment for Endometrial, Ovarian, and Cervical CancersMay 2022
CCO 2021 Global Conference Coverage: Gynecologic Cancer UpdatesNovember 2021
Expert Commentary and Insight on Key Data From SGO 2023 Informing Treatment for Endometrial, Cervical, and Ovarian CancersMay 2021
Existing and Emerging Strategies in the Management of Patients with Uterine SarcomasMarch 2017
Join now to see all

Press Mentions

These Tiny Beads May Offer Big Hope to Ovarian Cancer PatientsMay 1st, 2023
Multiple lawsuits claim hair relaxer products contain chemicals that can cause uterine cancerFebruary 27th, 2023
Carboplatin & Paclitaxel Chemotherapy Alone Should Remain Standard Treatment for Endometrial CancerSeptember 12th, 2019
Join now to see all

Professional Memberships

Texas Medical Association - TMA
Member
American College of Obstetricians and Gynecologists
Fellow
American College of Surgeons - ACS
Fellow
Society of Gynecologic Oncology
Member
Dallas County Medical Society
Member
Western Association of Gynecologic Oncology
Member
American Society of Clinical Oncology - ASCO
Member

External Links

University of Texas Southwestern Medical Centerhttp://www.utsouthwestern.edu/patientcare/doctor/findphysician/profile/0,0,14954_Dr_David_Miller_MD,00.html
American College of Surgeonshttp://web2.facs.org/acsdir/public/detailmember.cfm?CHKDGTS=00300008590
American Society of Clinical Oncologyhttp://www.asco.org/portal/site/ASCOv2/template.PAGE/member-directory/?javax.portlet.tpst=04f5ebfc0463247ad110dc104c37a01d_ws_MX&javax.portlet.prp_04f5ebfc0463247ad110dc104c37a01d_viewID=find_member_detail_view&javax.portlet.begCacheTok=com.vignette.cache